Lv51
1460 积分 2025-07-08 加入
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
4天前
已完结
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
4天前
已完结
HRS-5965, a small-molecule factor B inhibitor, in healthy participants and participants with renal insufficiency: A first-in-human, phase 1 trial
12天前
已完结
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
14天前
已完结
Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy
1个月前
已完结
Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition
2个月前
已完结
Guidelines for the diagnosis and treatment of rosacea in China （2021 edition）
2个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
2个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2个月前
已完结
皖公网安备34019202002308
